|   | 
        
            
         | 
          | 
        
        
        
            | 
                
             | 
         
        
             | 
         
        
            
            
            
  
    
	  | 
   
  
    
        
          |   | 
          
              
                | 
                    Á¦·Î¹«¿ø½º¿Ü¿ë¾×(Å׸£ºñ³ªÇÉ¿°»ê¿°) 5g  Zero-Moo Once Topical Soln.  
                    
                 | 
               
              
                | 
                     ÀϹÝÀǾàǰ | ºñ±Þ¿©  
                        
                    	
                    
                 | 
               
              
                | 
					  
                  
				  
                 | 
               
              
              
              
              
              |   |  
              
                
                    
                        | 
                      ¾Ë¸²:  | 
                      µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. | 
                     
                    | 
               
            
              
                
                   
                   
                   
                   
		   
                 | 
               
              
                | 
                  
                  
                 | 
               
              | 
            | 
         
       
       | 
   
    |  
  
    | 
      
     | 
     
  |  
                              
                                  | 
                                   | 
                               
            
            
                
            
            
              
            
                            
              
                                                     
            
            
   |  
  
    | 
      
     | 
   
   
     | 
   
    
   
    | 
       
        À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
        ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
        ·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
       
     | 
   
  
     | 
   
   
  
    
      
	
	  
	     |  
	    
	      
	        
            
                | Çã°¡Á¤º¸ | 
                         
	         
	       | 
	     
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× | 
    
      
      
        
        653006801  
	    
	    
          [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸] 
          
        
        
        
                    [ºñ±Þ¿©]
                
       
      
       
       
     
      
      
     
      
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
     [Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
     [¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
     | 
   
   
    | ºü¸¥Á¶È¸ | 
    
      
     |   
   
  
  
   
    | Á¦Ç°¼º»ó | 
    
      ¹«»ö ¶Ç´Â ¿¬ÇÑ Èò»öÀÇ Åõ¸íÇÑ ¿Ü¿ëÁ¦  
      
	    [Á¦ÇüÁ¤º¸ È®ÀÎ]
     |   
   
  
  
  
  
  
   
    | Æ÷À塤À¯Åë´ÜÀ§ | 
    5±×·¥/Æ©ºê | 
   
  
  
  
  
  	
   
    | ÁÖ¼ººÐÄÚµå | 
    
      235748CLQ  
      
	  [µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
     | 
   
  
  
  
  
  	
   
    | ´ëÇ¥ÄÚµå | 
    8806530068006 | 
   
  
  
  
  
   
    | º¸°ü¹æ¹ý | 
    ±â¹Ð¿ë±â, 15¢¦30¡Éº¸°ü | 
   
  
  
  
  
  
  
   
    | È¿´ÉÈ¿°ú | 
    
    [ÀûÀÀÁõ º° °Ë»ö] 
      
    
     
	 
      Trichophyton (T. rubrum, T. mentagrophytes, T.verrucosum, T. violaceum), Microsporum canis ¹× Epidermophyton floccosum °ú °°Àº ÇǺλç»ó±Õ¿¡ ÀÇÇÑ ÇǺΰ¨¿°Áõ : Á·ºÎ¹é¼±(¹ß¹é¼±Áõ,¹«Á»)(15¼¼ ÀÌ»óÀÇ Ã»¼Ò³â ¹× ¼ºÀο¡ ÇÑÇÔ) 
      
      
      
      
     | 
   
  
  
  
  
  
  
  
  
    
  
  
   
    | ¿ë¹ý¿ë·® | 
    
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù. 
    
     
      
      
     [󹿾à¾î] 
      ÀÌ ¾àÀº ´Ü 1ȸ Àû¿ëÇÑ´Ù. 
Àû¿ë Àü¿¡ ȯºÎ¸¦ ±ú²ýÀÌ ¾Ä°í, ¿ÏÀüÈ÷ °ÇÁ¶½ÃŲ ÈÄ È¯ºÎ¿Í ±× ÁÖÀ§°¡ ÃæºÐÈ÷ Àû¼ÅÁöµµ·Ï ÃæºÐÇÑ ¾çÀ» ¹Ù¸¥´Ù. 
Áø±ÕÀÇ ¿Ïº®ÇÑ Ä¡·á¸¦ À§Çؼ´Â º´¼Ò°¡ ³ªÅ¸³ªÁö ¾ÊÀº ÂÊ ¹ßÀ̶ó ÇÒÁö¶óµµ, ¾çÂÊ ¹ß ¸ðµÎ¿¡ Àû¿ëÇÑ´Ù. ÀÌ ¾àÀ» ¹ß°¡¶ô »çÀÌ ¸ðµÎ ¾ã°Ô Æì ¹Ù¸£°í ¹ß¹Ù´Ú Àüü¿Í ¹ß¹Ù´ÚÀ¸·ÎºÎÅÍ ¾à 1.5cm ³ôÀ̱îÁö ÀÌ ¾àÀ» Àû¿ëÇϸç 1~2ºÐ°£ °ÇÁ¶½ÃŲ´Ù. ÀÌ ¾à Àû¿ë ½Ã¿¡´Â ¹®Áú·¯ ¹Ù¸£Áö ¾Ê´Â´Ù. »ç¿ë ÈÄ¿¡´Â ¼ÕÀ» ±ú²ýÀÌ ¼¼Ã´ÇÑ´Ù. 
ÀÌ ¾àÀÇ È¿°ú¸¦ ³ôÀÌ·Á¸é Àû¿ë ÈÄ 24½Ã°£ µ¿¾È ¾ÄÁö ¾Ê°í ±×´ë·Î µÐ´Ù. 1ÁÖ°¡ Áö³ ÈÄ¿¡µµ °³¼±ÀÇ Â¡Èİ¡ º¸ÀÌÁö ¾ÊÀ¸¸é, Àǻ糪 ¾à»ç¿Í »ó´ãÇÑ´Ù.      
      	    
     | 
   
  
  
  
  
  
  
  
  
  
   
    | ±Ý±â | 
    
       1) Å׸£ºñ³ªÇÉ ¹× ÀÌ ¾à ¼ººÐ¿¡ °ú¹ÎÁõ ¶Ç´Â ±× º´·ÂÀÌ Àִ ȯÀÚ 
2) ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ ¹× ¼öÀ¯ºÎ 
3) À¯¡¤¼Ò¾Æ 
     | 
   
  
  
  
  
   
    | ½ÅÁßÅõ¿© | 
    ÀÌ ¾àÀº ÇÁ·ÎÇÊ·»±Û¸®ÄÝÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î ÀÌ ¼ººÐ¿¡ °ú¹ÎÇϰųª ¾Ë·¹¸£±â º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.  | 
   
  
  
  
   
    | ÀÌ»ó¹ÝÀÀ | 
    
       ÇǺÎÀÇ µÎµå·¯±â, ¹ßÀû, È«¹Ý, °¡·Á¿ò, Àڱذ¨, ±¹¼ÒÀÇ Á¢ÃËÇǺο°, ÇǺιڸ®, ÀÚÅë(í©÷Ô), ÀÛ¿°¨ÀÌ Àû¿ëºÎÀ§¿¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù. 
          
     | 
   
  
  
    
   
    | ÀϹÝÀû ÁÖÀÇ | 
    1) °úµµÇÑ ÀÚ±ØÀÌ ³ªÅ¸³ª°Å³ª ´õ ½ÉÇØÁö¸é Åõ¿©¸¦ ÁßÁöÇϰí ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »óÀÇÇÑ´Ù. 
2) ÀÇ»çÀÇ Áö½Ã°¡ ¾ø´Â ÇÑ ¹ÐºÀºØ´ë¹ý ¶Ç´Â Æ÷Àå¹ýÀ» »ç¿ëÇÏÁö ¾Ê´Â´Ù. 
3) ÀÌ ¾à¿¡ ´ëÇÑ ¹ÝÀÀÀÌ ³ªÅ¸³ªÁö ¾ÊÀ¸¸é Áø±ÕÇÐÀûÀÎ °Ë»ç¸¦ ½Ç½ÃÇÏ¿© ´Ù¸¥ º´¿ø±Õ¿¡ ÀÇÇÑ °¨¿° ¿©ºÎ È®ÀÎ ÈÄ ´Ù¸¥ Ç×Áø±Õ¿ä¹ýÀ» ½ÃÇàÇÑ´Ù. 
4) ¿¡Åº¿Ã µîÀÇ ¾ËÄڿüº ±âÁ¦°¡ ±¹¼ÒÀÚ±ØÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ¿µ¡¤À¯¾Æ ¶Ç´Â Á¡¸·ºÎÀ§¿¡ ÀÌ ¾à Åõ¿©½Ã ÁÖÀÇÇÑ´Ù. 
5) ¼Õ»óµÇÁö ¾ÊÀº ÇǺο¡ ÀÖ¾î¼ ÀÌ ¾àÀÇ ÀçÈí¼öÀ²ÀÌ ³·¾Æ¼ Àü½ÅÀû È¿°ú°¡ ³ªÅ¸³¯ °¡´É¼ºÀº Èñ¹ÚÇϳª »óóºÎÀ§, ³ÐÀº ºÎÀ§, ¿µ¾Æ(Ç¥¸éÀû/üÁßÀÇ ºñÀ² ¹× ¹è³»¿ÊÀÇ ¹ÐºÀ È¿°ú)ÀÇ °æ¿ì¿¡´Â Àü½ÅÀû È¿°ú°¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù.  | 
   
  
  
  
  
  
  
   
    | ÀӺο¡ ´ëÇÑ Åõ¿© | 
    
      
	[ÀӺαݱ⠼ººÐ Á¶È¸]       
      µ¿¹°¿¡ ´ëÇÑ »ý½Äµ¶¼º½ÇÇè¿¡¼ ÅÂÀÚµ¶¼ºÀÇ À§Ç輺ÀÌ º¸°íµÇÁö´Â ¾Ê¾ÒÁö¸¸, ÀÓ½ÅÁßÀÇ Åõ¿©¿¡ °üÇÑ ¾ÈÀü¼ºÀÌ È®¸³µÇ¾î ÀÖÁö ¾ÊÀ¸¹Ç·Î ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀο¡´Â Ä¡·á»óÀÇ À¯ÀͼºÀÌ À§Ç輺À» »óȸÇÑ´Ù°í ÆÇ´ÜµÇ´Â °æ¿ì¿¡¸¸ Åõ¿©ÇÑ´Ù. 
     | 
   
  
  
  
  
   
    | ¼öÀ¯ºÎ¿¡ ´ëÇÑ Åõ¿© | 
    ÀÌ ¾àÀº ¸ðÀ¯·Î ºÐºñµÇ¹Ç·Î, ÀÌ ¾àÀ» Åõ¿©ÁßÀÎ ¼öÀ¯ºÎ´Â ¼öÀ¯¸¦ Áß´ÜÇÑ´Ù.  | 
   
  
  
  
  
   
    | ¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿© | 
    
      
       
      º»Á¦Ç°Àº 15¼¼ ¹Ì¸¸ÀÇ ¼Ò¾Æ¿¡ ´ëÇØ ¾ÈÀü¼º ¹× À¯È¿¼ºÀÌ È®¸³µÇ¾î ÀÖÁö ¾ÊÀ¸¹Ç·Î ÀÌ ¾àÀ» 15¼¼ ¹Ì¸¸ÀÇ ¼Ò¾Æ¿¡ Åõ¿©ÇÏÁö ¾Ê´Â´Ù (À¯¡¤¼Ò¾Æ¿¡ ´ëÇÑ »ç¿ë°æÇèÀÌ Àû´Ù).  | 
   
  
  
  
  
  
  
  
  
  
  
  
    
   
    | Àû¿ë»óÀÇ ÁÖÀÇ | 
    1) ÀÌ ¾àÀº ¿Ü¿ëÀ¸·Î¸¸ Àû¿ëÇÑ´Ù. 
2) ¾È°ú¿ëÀ¸·Î °¢¸·, °á¸·¿¡ »ç¿ëÇÏÁö ¾Ê´Â´Ù. ½Ç¼ö·Î ´«¿¡ µé¾î°¬À» °æ¿ì¿¡´Â ÃæºÐÇÑ ¾çÀÇ ¹°·Î ¿ÏÀüÈ÷ ¾Ä¾î ³½´Ù. 
3) ¼ÕÅé, µÎÇÇ, ÀÔÁÖÀ§ ¹× ÁúºÎÀ§¿¡ »ç¿ëÇÏÁö ¾Ê´Â´Ù. 
4) ÀÚ±ØÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ±Õ¿(°¥¶óÁü), ¹Ì¶õ(Áþ¹«¸§) ºÎÀ§¿¡´Â ÁÖÀÇÇÏ¿© »ç¿ëÇÑ´Ù.  | 
   
  
  
  
   
    | °ú·®Åõ¿© ¹× óġ | 
    ½Ç¼ö·Î ÀÌ ¾àÀ» º¹¿ëÇÑ °æ¿ì¿¡´Â À§¼¼Ã´ µîÀÇ ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.  | 
   
  
  
  
  		
  
  
   
    | º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ | 
    1) ¾î¸°ÀÌÀÇ ¼ÕÀÌ ´êÁö ¾Ê´Â °÷¿¡ º¸°üÇÑ´Ù. 
2) 15¡30¡É¼ º¸°üÇÑ´Ù.  | 
   
  	
  
  
  
  
  
  
   
    | Related FDA Approved Drug | 
    
       
     | 
      
  
  
      							
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¤º¸¿ä¾à | 
                 
	         
	       | 
	           	    
	     |  
	    | 
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
    
  
  
    
  
   |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ÄÚµå ¹× ºÐ·ùÁ¤º¸ | 
                 
	         
	       | 
	           	    
	     |  
	    | 	 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¦Ç°Á¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | º¹¾àÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
   
    | LACTmed ¹Ù·Î°¡±â | 
    
      
        [¹Ù·Î°¡±â]
     | 
     
  
  
  
  
   
    | Ãà¾àº¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
       
  
  
   
    | º¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
                                                          															
  
   
  
  
   
    | ÀӺο¡´ëÇÑÅõ¿© | 
    
      
      
        
	      
	      
	        | *  | 
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	         | 
	         
	       
	       | 
	   
	  
	    |   | 
	   
	  
	    
	      FDA : Bµî±Þ 
				        
				         (terbinafine; )
				        
	   | 
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   | 
	 
	
	  
	      
	      
	        | *  | 
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
	         | 
	         
	      
	        | *  | 
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
	         | 
	         
	       
	   | 
	 
       
     | 
   
  
  
  	   
  
  	   
  
  	   
  
  
  
  
  
  
  
  	
  
  
  
   
    | º¹¾à¶óº§ | 
    
    
    
      | À̹ÌÁö | 
      º¹¾à¼³¸í | 
     
    
    
        | 
      ÀÓ»êºÎ ¶Ç´Â ÀӽŰèȹÁß º¹¿ë±ÝÁö | 
     
    
       | 
     
    
     |  
    
      
	
	  
            | *  | 
	    º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. | 
	   
	  
            | *  | 
	    º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. | 
	   
	  
            | *  | 
	    ±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. | 
	   
	   
     |   
     | 
   
  	
  
  
  
   
    | º¸°ü»ó ÁÖÀÇ | 
    
      
    	
     | 
   
  
  
   
    | Á¶Á¦½Ã ÁÖÀÇ | 
    
      
    	
     | 
      
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ½É»çÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | ÇмúÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
    | DUR (ÀǾàǰ»ç¿ëÆò°¡) | 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	  [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]										
	  ¿¬·É´ë±Ý±â :
      °í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
      
       [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
       
       
        
        
     | 
   
  
   
    | Mechanism of Action | 
    
       Terbinafine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Terbinafine is hypothesized to act by inhibiting squalene epoxidase, thus blocking the biosynthesis of ergosterol, an essential component of fungal cell membranes. 
     | 
   
  
   
    | Pharmacology | 
     
       Terbinafine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Terbinafine is an allylamine antifungal agent and acts by inhibiting squalene epoxidase, thus blocking the biosynthesis of ergosterol, an essential component of fungal cell membranes. in vitro, mammalian squalene epoxidase is only inhibited at higher (4000 fold) concentrations than is needed for inhibition of the dermatophyte enzyme. Depending on the concentration of the drug and the fungal species test in vitro, Terbinafine may be fungicidal. However, the clinical significance of in vitro data is unknown. 
     | 
   
  
   
    | Metabolism | 
    
       Terbinafine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2D6 (CYP2D6) 
     | 
   
  
   
    | Absorption | 
    
       Terbinafine¿¡ ´ëÇÑ Absorption Á¤º¸ Readily absorbed from gastrointestinal tract. 
     | 
   
  
   
    | Toxicity | 
    
       Terbinafine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available 
     | 
   
  
   
    | Drug Interactions | 
    
       Terbinafine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available 
     | 
   
  
   
    CYP450  Drug Interaction | 
    
      [CYP450 TableÁ÷Á¢Á¶È¸] 
     | 
   
  
   
    | Drug Target | 
    
      
      [Drug Target]
     | 
   
  
   
    | Description | 
    
       Terbinafine¿¡ ´ëÇÑ Description Á¤º¸ Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal. It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene epoxidase, an enzyme that is part of the fungal cell wall synthesis pathway. 
     | 
   
  
   
    | Dosage Form | 
    
       Terbinafine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Cream	TopicalSpray	TopicalTablet	Oral 
     | 
   
  
   
    | Drug Category | 
    
       Terbinafine¿¡ ´ëÇÑ Drug_Category Á¤º¸ AllylaminesAntifungal AgentsAntifungalsEnzyme InhibitorsTrypanocidal Agents 
     | 
   
  
   
    | Smiles String Canonical | 
    
       Terbinafine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN(CC=CC 
     | 
   
  
   
    | Smiles String Isomeric | 
    
       Terbinafine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN(C\C=C\C 
     | 
   
  
   
    | InChI Identifier | 
    
       Terbinafine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3 
     | 
   
  
   
    | Chemical IUPAC Name | 
    
       Terbinafine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine 
     | 
   
    
  |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | »ç¿ëÀÚÄÁÅÙÃ÷ | 
                             
	         
	       | 
	           	  
       |  
	     |  
	   
	     	
 
  | 
   
   
     | 
   
  
    
      
        
          
            
              - 
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-01-06
              
 
              - 
                
                º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                
              
     
             
         |                 
       
     |       
          
                
                    
                       ¾Ë¸² | 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  | 
                    
                    | 
               
      
      
                
                    
                       °æ°í | 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 | 
                    
                    | 
               
  
 
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
   
  
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
 
  
  |  
             
             | 
         
         
         | 
         |